Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol.
We tried to evaluate the role of dosimetry-guided transarterial radionuclide therapy (TART) with rhenium-188 (Re-188)-4-hexadecyl 1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol (HDD)-lipiodol in a patient with multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma (HCC). The dosimetry helped in delivering the maximum possible activity of Re-188, thus the radiation-absorbed dose, safely to the tumour without jeopardizing other organs. There was no procedure-related complication and the patient tolerated therapy well with no adverse effects. The lesions were completely ablated with a single dose of Re-188 and the patient has been disease free for the past 18 months. TART with Re-188-HDD-lipiodol appears to be a promising therapeutic option in patients with HCC who experience recurrence after percutaneous ablative therapy.
Kumar
Ajay
A
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India, 110029. kumar_drajay@rediffmail.com
Bal
Chandrasekhar
C
Srivastava
Deep Narayan
DN
Thulkar
Sanjay Prayagraj
SP
Sharma
Sanjay
S
Acharya
Subrato Kumar
SK
Duttagupta
Siddharta
S
D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000601:surgery; D017115:Catheter Ablation; D006801:Humans; D007459:Iodized Oil / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000601:surgery; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011874:Radiometry / Q000379:methods; D012211:Rhenium / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D011868:Radioisotopes; D012211:Rhenium; D007459:Iodized Oil